TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families

Hereditary Cancer in Clinical Practice

Volumn 12, Issue 1, 2014, Pages

  Cury, Nathalia M ^a,b   Ferraz, Victor E F ^a   Silva Jr, Wilson A ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute of Science and Technology in Stem Cell and Cell Therapy (INCTC)   (Brazil)

Author keywords

BRCA1; Breast cancer; High resolution melting; TP53 mutation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADULT; ARTICLE; BRAZIL; CANCER PATIENT; CANCER RISK; CASE REPORT; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MEDICAL SOCIETY; PAROTID GLAND CANCER; PRACTICE GUIDELINE; PREVALENCE;

EID: 84899133320     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-12-8     Document Type: Article

References (31)

1. WHO. World Health Organization [http://www.who.int], WHO. World Health Organization.
2. INCA. National Cancer Institute Rio de Janeiro: Cancer Incidence in Brazil, Ministry of Health. Department of Health Care Coordination for Prevention and Surveillance. Estimate 2012, [http://www2.inca.gov.br], INCA. National Cancer Institute.
3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77(11):2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z, 8635102.
4. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295(12):1379-1388. 10.1001/jama.295.12.1379, 16551709.
5. Chacon RD, e Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010, 12(Suppl 2):S3.
6. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5(1):5-23. 10.1016/j.molonc.2010.11.003, 21147047.
7. Schneider K. Counseling about cancer: strategies for genetic counseling 2002, New York: Wiley-Liss, 2.
8. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238. 10.1126/science.1978757, 1978757.
9. Li FP, e Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969, 71(4):747-752. 10.7326/0003-4819-71-4-747, 5360287.
10. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10(2):83-87.
11. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54(5):1298-1304.
12. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
13. Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000, 82(12):1932-1937. 2363254, 10864200.
14. NCCN - National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology TM. Genetic/Familial High-Risk Assessment: Breast and Ovarian 2013, Li-Fraumeni Syndrome (LIFR-1). V.4, http://www.nccn.org, NCCN - National Comprehensive Cancer Network.
15. Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012, 14(2):R66. 10.1186/bcr3172, 3446401, 22507745.
16. Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC. Impact of Neonatal Screening and Surveillance for the TP53 TP53 P.R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013, 31(20):2619-2626. 10.1200/JCO.2012.46.3711, 23733769.
17. Achatz MI, Olivier M, le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, da Rocha JC, Vettore AL, Hainaut P. The TP53 mutation, TP53 P.R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245(1-2):96-102.
18. Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA. Association of the germline TP53 TP53 P.R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008, 8:357. 10.1186/1471-2407-8-357, 2631588, 19046423.
19. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI. Detailed haplotype analysis at the TP53 locus in p.TP53 P.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010, 31(2):143-150. 10.1002/humu.21151, 19877175.
20. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P. Detection of TP53 P.R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008, 261(1):21-25. 10.1016/j.canlet.2007.10.044, 18248785.
21. NCCN - National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology™. Genetic/Familial High-Risk Assessment: Breast and Ovarian 2010, Hereditary Breast and/or Ovarian Cancer (HBOC-1) V.1, http://www.nccn.org, NCCN - National Comprehensive Cancer Network.
22. Bastien R, Lewis TB, Hawkes JE, Quackenbush JF, Robbins TC, Palazzo J, Perou CM, Bernard PS. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat 2008, 29(5):757-764. 10.1002/humu.20726, 18348286.
23. de Leeneer K, Coene I, Poppe B, de Paepe A, Claes K. Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clin Chem 2008, 54(6):982-989. 10.1373/clinchem.2007.098764, 18403564.
24. Keshavarzi F, Javadi GR, Zeinali S. BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer 2012, 11(1):57-67. 10.1007/s10689-011-9477-3, 21918854.
25. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48(18):5358-5362.
26. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27(26):e108-e109. author reply e110, 10.1200/JCO.2009.22.7967, 19652052.
27. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001, 86(10):4970-4973. 10.1210/jcem.86.10.7957, 11600572.
28. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC. Penetrance of adrenocortical tumours associated with the germline TP53 TP53 P.R337H mutation. J Med Genet 2006, 43(1):91-96. 2564508, 16033918.
29. Digiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002, 9(1):12-16. 10.1038/nsb730, 11753428.
30. Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A, Pitombo MB, Leal PR F, Royer R, Zhang P, Narod SA. The TP53 P.R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012, 10(1):3. 10.1186/1897-4287-10-3, 3341178, 22455664.
31. Mccuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D. Routine TP53 testing for breast cancer under age 30: ready for prime time?. Fam Cancer 2012, 11(4):607-613. 10.1007/s10689-012-9557-z, 22851211.